2024-02-01 13:20:32 ET
Summary
- Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia.
- In this article I'll look at Casgevy's market potential and its commercialisation challenges.
- The cost of Casgevy, treatment cons, scalability and accessibility pose serious challenges for widespread adoption. Which may justify the high short interest in the stock.
Crispr Therapeutics ( CRSP ) recently received approval for their gene editing therapy, CASGEVY used for treating inherited illnesses Sickle Cell Disease and Beta-Thalassemia....
Read the full article on Seeking Alpha
For further details see:
Crispr Therapeutics: Investors Bet Against Casgevy Uptake